Solid Biosciences (SLDB) Cash & Current Investments (2017 - 2026)

Solid Biosciences has disclosed Cash & Current Investments across 10 years of filings, most recently posting $380.7 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $380.7 million, up 80.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $380.7 million (up 80.73% YoY), and the FY2025 annual result was $187.8 million, up 134.12% from the prior year.
• Cash & Current Investments came in at $380.7 million for Q1 2026 at Solid Biosciences, up from $187.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $380.7 million in Q1 2026 to a low of $54.5 million in Q2 2022.
• The 5-year median for Cash & Current Investments is $185.5 million (2023), against an average of $184.3 million.
• Across the five-year window, Cash & Current Investments plunged 72.82% in 2022 and soared 193.67% in 2023, its largest moves.
• Solid Biosciences' Cash & Current Investments stood at $213.7 million in 2022, then slumped by 42.15% to $123.6 million in 2023, then plunged by 35.11% to $80.2 million in 2024, then surged by 134.12% to $187.8 million in 2025, then soared by 102.65% to $380.7 million in 2026.
• The last three Cash & Current Investments figures came in at $380.7 million (Q1 2026), $187.8 million (Q4 2025), and $236.1 million (Q3 2025), per Business Quant data.